Title

A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

UMMS Affiliation

Meyers Primary Care Institute; Department of Medicine, Division of Geriatric Medicine

Publication Date

6-1-1995

Document Type

Article

Subjects

Aged; Cost-Benefit Analysis; Decision Support Techniques; Humans; Models, Economic; Myocardial Infarction; Quality-Adjusted Life Years; Streptokinase; Thrombolytic Therapy; Tissue Plasminogen Activator

Disciplines

Health Services Research | Medicine and Health Sciences

Abstract

OBJECTIVE: To assess the short- and long-term costs and clinical and quality of life outcomes with the use of streptokinase (SK) vs tissue plasminogen activator (tPA) for acute myocardial infarction (MI). DESIGN: A decision analysis model. PATIENTS: Patients with acute MI who were candidates for thrombolytic therapy and who presented within six hours of symptom onset. MEASUREMENTS: 30-day and one-year mortality, impacts of disabling and nondisabling stroke, reinfarction, hemorrhage, hypotension, anaphylaxis, and long-term medical costs. RESULTS: Using 30-day mortality data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, the baseline analysis yielded an incremental cost-effectiveness for tPA of $30,300 per additional quality-adjusted life year (QALY) gained, compared with SK. Using one-year mortality data from the GUSTO trial, the analysis yielded an incremental cost-effectiveness for tPA of $27,400 per additional QALY, compared with SK. The incremental cost-effectiveness of tPA over SK was sensitive to the difference in mortality seen with the two agents, exceeding $100,000 per QALY, for a relative survival advantage of approximately one-third that seen in the GUSTO trial. The incremental cost per QALY of tPA remained under $60,000 if the survival benefit was half that seen in the GUSTO trial. The cost-effectiveness of tPA declined with a shorter projected life expectancy following MI and for inferior (vs anterior) wall infarction. The analysis was modestly sensitive to the costs of the thrombolytic agents. CONCLUSIONS: In spite of its higher cost relative to SK, tPA is a cost-effective therapy for MI under a wide range of assumptions regarding clinical outcomes and costs.

Source

J Gen Intern Med. 1995 Jun;10(6):321-30.

Journal/Book/Conference Title

Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine

Related Resources

Link to article in PubMed

PubMed ID

7562123

This document is currently not available here.

Share

COinS